Name: Argipressin
Brand: Creative Peptides
Rating: 5 (1 reviews)

M.F/Formula

C46H65N15O12S2

M.W/Mr.

1084.2

Sequence

One Letter Code:CYFQNCPRG
Three Letter Code:H-Cys(1)-Tyr-Phe-Gln-Asn-Cys(1)-Pro-Arg-Gly-NH2

Labeling Target

Oxytocin/Vasopressin (V2, V1a, V1b) receptor

Application

Central diabetes insipidus;
Variceal bleeding;
Vasoconstrictor in local anaesthetic injections

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Areas of Interest

Cardiovascular System & Diseases
Pituitary & Hypothalamic Hormones
Veterinary Medicine

Target

Vasopressin Receptor

Argipressin, also known as vasopressin or antidiuretic hormone (ADH), is a naturally occurring peptide hormone with crucial roles in water homeostasis and vascular regulation in mammals. As a nonapeptide, it is structurally characterized by a cyclic arrangement of amino acids, which confers high specificity in receptor binding and biological activity. In the context of biochemical and physiological research, Argipressin holds significant value as a tool for investigating neuroendocrine signaling pathways, osmoregulatory mechanisms, and the modulation of vascular tone. Its well-defined receptor interactions and downstream effects make it a pivotal compound for elucidating peptide hormone function and for the development of receptor-targeted studies.

Receptor Pharmacology: Argipressin is extensively utilized in receptor pharmacology to probe the activity and specificity of vasopressin receptors, particularly V1a, V1b, and V2 subtypes. By serving as a reference agonist in binding and functional assays, it enables researchers to characterize receptor-ligand interactions, assess receptor density, and evaluate signal transduction mechanisms. These studies are essential for advancing the understanding of G protein-coupled receptor (GPCR) biology and for facilitating the discovery of novel receptor modulators.

Signal Transduction Studies: In cellular and molecular research, Argipressin is applied to dissect intracellular signaling cascades triggered by peptide hormone binding. Its ability to induce well-characterized second messenger responses, such as increases in intracellular calcium or cAMP, allows for the detailed analysis of downstream effectors and regulatory feedback mechanisms. Such investigations provide foundational insights into hormone-regulated cellular processes and the broader dynamics of neuroendocrine control.

Water Transport and Osmoregulation Research: As the principal antidiuretic hormone, Argipressin is indispensable in studies focused on renal physiology and water reabsorption. Researchers employ it to model and quantify the regulation of aquaporin channels in renal collecting ducts, thereby elucidating the molecular basis of water balance and osmoregulatory adaptation. These applications are particularly relevant for understanding disorders of water homeostasis and for validating experimental models of kidney function.

Vascular Function and Smooth Muscle Studies: The peptide's potent vasoconstrictive properties make it a standard agent in vascular biology and smooth muscle research. By applying Argipressin to isolated tissue preparations or in vitro cell systems, scientists can investigate mechanisms of vascular tone regulation, endothelial signaling, and smooth muscle contraction. Such studies contribute to the broader understanding of cardiovascular physiology and the interplay between neurohormonal and vascular systems.

Peptide Synthesis and Analytical Reference: Owing to its well-characterized structure and bioactivity, Argipressin serves as a benchmark compound in peptide synthesis and analytical method development. It is frequently used as a positive control in chromatographic assays, mass spectrometry, and peptide quantification protocols. Its inclusion in these workflows ensures method reliability, supports the validation of synthetic protocols, and enables the accurate comparison of novel peptide analogs or modified derivatives.

Source#

Synthetic

Long-term Storage Conditions

Soluble in DMSO

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Short-term Storage Conditions

Dry, dark and at 0 - 4 °C

Solubility

-20 °C

Organism

Human

InChI

InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1

InChI Key

KBZOIRJILGZLEJ-LGYYRGKSSA-N

Canonical SMILES

C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N

Isomeric SMILES

C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N

BoilingPoint

N/A

References

The stress-induced release of ACTH is believed to involve the activation of several humoral and neural pathways, including corticotropin-releasing factor (CRF), catecholamines and vasopressin. The essential role of CRF was supported by our observation that immunoneutralization of this releasing factor significantly lowers plasma ACTH levels of ether-stressed rats. However, the presence of a small but measurable residual ACTH secretion suggested the possible involvement of factors other than CRF in the stress response. We report here that pretreatment with a vasopressin antagonist decreases the plasma ACTH levels of ether-stressed rats in later (10-20 min), but not earlier (0-10 min), phases of ether stress. The ganglionic blocker chlorisondamine, inhibits ACTH release during both phases of the response to ether by 40-60% when used alone, and by 100% when administered with anti-CRF antibody. These results support a role of CRF, catecholamines and vasopressin in mediating ACTH release by ether stress.

Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin[J]. Nature, 1983, 305(5932): 325-327.

The rationale for an arginine vasopressin (argipressin) infusion was put forward after it was discovered that patients in shock states might have an endogenous arginine vasopressin deficiency. Subsequently, several investigations impressively demonstrated that arginine vasopressin can successfully stabilise haemodynamics even in advanced vasodilatory shock. We report on physiological and pharmacological aspects of arginine vasopressin, and summarise current clinical knowledge on employing a continuous arginine vasopressin infusion in critically ill patients with catecholamine-resistant vasodilatory shock of different aetiologies. In view of presented experimental evidence and current clinical experience, a continuous arginine vasopressin infusion of approximately 2 to approximately 6 IU/h can be considered as a supplemental strategy to vasopressor catecholamines in order to preserve cardiocirculatory homeostasis in patients with advanced vasodilatory shock. Because data on adverse effects are still limited, arginine vasopressin should be reserved for patients in whom adequate haemodynamic stabilisation cannot be achieved with conventional vasopressor therapy or who have obvious adverse effects of catecholamines that result in further significant haemodynamic deterioration. For the same reasons, arginine vasopressin should not be used as a single, alternative vasopressor agent instead of catecholamine vasopressors. Future prospective studies will be necessary to define the exact role of arginine vasopressin in the therapy of vasodilatory shock.

Dünser M W, Wenzel V, Mayr A J, et al. Management of vasodilatory shock[J]. Drugs, 2003, 63(3): 237-256.

Melting Point

N/A

1. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide

2. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

3. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

5. Cationic cell-penetrating peptides are potent furin inhibitors